EC secures 300 million doses of COVID-19 vaccine
The European Commission has reserved 300 million doses from Sanofi SA’/GSK plc’s adjuvanted recombinant COVID-19 vaccine.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2068 entries already.
Entries by Thomas Gabrielczyk
Roche’s IL-6 receptor blocker fails in Phase III
Roche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.
Enthera Pharmaceuticals Srl raises €28m in Series A financing
Italian start-up Enthera Pharmaceuticals has raised €28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
Vital expertise in oncolytic virus production
Oncolytic viruses, viral vectors for gene therapy and viral-vectored prophylactic vaccines, are new, innovative, and already successful approaches for the treatment of severe diseases. The production of these viruses requires extensive experience and specially-designed GMP clean rooms. Vibalogics offers both.
Polyphor AG bags CHF19.3 in equity financing
Swiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.
A plucked chicken named Horizon Europe
According to current information, the European Research Framework Programme "Horizon Europe" is likely to be among the indirect victims of the Corona pandemic: A large part of the funds earmarked will now go to the € 750 billion rescue fund.
Defining the bioprocess is early quality control
As the process determines the product, product characteristics of biological drugs need to be analysed thoroughly right from the beginning of the drug development process. Early understanding of structure-function relationships, aggregation, microheterogenicity, and glycosylation, and more, helps minimise development risks.
Quantro: Seed capital by Evotec and Boehringer
Germany’s Evotec SE and Boehringer Ingelheim Venture Fund have acquired equal minority stakes in Quantro Therapeutics GmbH, a recently established research-based biotech company based in Vienna. Evotec also entered into a comprehensive partnership with the Austrian start-up, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases. The Germans will provide hit identification services for Quantro’s proprietary anti-tumour projects.
Sourcing reference products
A biosimilar is a copy version of an approved, original biological medice whose patent protection has expired. The development strategies for biosimilar product and a new biological entity (NBE) differ in many ways.
Targeting coronaviruses
Viennese APEIRON Biologics AG raised €17.5m to expand ongoing Phase II trials of its
coronavirus-specific drug candidate APN01 in Europe to the US and Russia. The recombinant angiotensin-converting enzyme 2 (rhACE2) mimics the receptor on the human cells that coronaviruses are using to infect these cell. Preclinical and clinical data demonstrate that APN01 is well-tolerated and can stop the overshooting host immune responses that are triggered by virus proliferation.